Next Article in Journal
Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential
Next Article in Special Issue
Development of a Nucleic Acid Lateral Flow Immunoassay for the Detection of Human Polyomavirus BK
Previous Article in Journal
Biochemical Markers of Saliva in Lung Cancer: Diagnostic and Prognostic Perspectives
Previous Article in Special Issue
A Pervasive Healthcare System for COPD Patients
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Multiplex Point-of-Care Tests for the Determination of Antibodies after Acellular Pertussis Vaccination

1
Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
2
Department of Biotechnology, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
3
Department of Pediatrics and Adolescent Medicine, Turku University Hospital, Kiinamyllynkatu 4-8, 20520 Turku, Finland
4
Department of Medical Microbiology, Capital Medical University, No.10 Xi Tou Tiao, You’an Men Wai, Feng Tai District, Beijing 100069, China
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(4), 187; https://doi.org/10.3390/diagnostics10040187
Submission received: 28 February 2020 / Revised: 18 March 2020 / Accepted: 26 March 2020 / Published: 27 March 2020

Abstract

Most of the current serological diagnosis of pertussis is based on pertussis toxin (PT) IgG antibodies and does not differentiate between vaccination and infection-induced antibodies. PT is included in all of acellular pertussis vaccines available in the world. Multiplex testing of non-vaccine antigen-related antibodies has the potential to improve the diagnostic outcome of these assays. In this study, we developed a quantitatively spatial multiplex lateral flow immunoassay (LFIA) for the detection of IgG antibodies directed against PT, pertactin (PRN), and filamentous hemagglutinin (FHA). The assay was evaluated with serum samples with varying anti-PT, anti-PRN, and anti-FHA IgG levels and the result was compared to those obtained with standardized ELISA. The developed assay showed good specificity with PT and PRN antibodies and semiquantification throughout the antigen combinations. This exploratory study indicates that the multiplex LFIA is specific and sensitive, and a similar test platform with alternative antigens could be suitable for new type of pertussis serology.
Keywords: pertussis; in vitro-diagnostics; point-of-care; serology; lateral flow; multiplex pertussis; in vitro-diagnostics; point-of-care; serology; lateral flow; multiplex

Share and Cite

MDPI and ACS Style

Knuutila, A.; Rautanen, C.; Mertsola, J.; He, Q. Multiplex Point-of-Care Tests for the Determination of Antibodies after Acellular Pertussis Vaccination. Diagnostics 2020, 10, 187. https://doi.org/10.3390/diagnostics10040187

AMA Style

Knuutila A, Rautanen C, Mertsola J, He Q. Multiplex Point-of-Care Tests for the Determination of Antibodies after Acellular Pertussis Vaccination. Diagnostics. 2020; 10(4):187. https://doi.org/10.3390/diagnostics10040187

Chicago/Turabian Style

Knuutila, Aapo, Carita Rautanen, Jussi Mertsola, and Qiushui He. 2020. "Multiplex Point-of-Care Tests for the Determination of Antibodies after Acellular Pertussis Vaccination" Diagnostics 10, no. 4: 187. https://doi.org/10.3390/diagnostics10040187

APA Style

Knuutila, A., Rautanen, C., Mertsola, J., & He, Q. (2020). Multiplex Point-of-Care Tests for the Determination of Antibodies after Acellular Pertussis Vaccination. Diagnostics, 10(4), 187. https://doi.org/10.3390/diagnostics10040187

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop